Zogenix, Inc.
NASDAQ: ZGNX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Stephen Farr
- Employees
- 327
- Headquarters
- Emeryville, United States
- IPO year
- 2010
- Website
- https://www.zogenix.com
Loading ZGNX…
Loading profile data…Frequently asked questions about ZGNX
What does Zogenix, Inc. (ZGNX) do?
Zogenix, Inc. is a biopharmaceutical company dedicated to the discovery, development, and commercialization of therapies for rare diseases within the United States, striving to profoundly improve the quality of life for affected patients and their families. Their flagship product candidate, Fintepla, a low-dose fenfluramine, is currently undergo...
Where does ZGNX trade?
Zogenix, Inc. (ZGNX) trades on the NASDAQ Global Market.
What sector is ZGNX in?
Zogenix, Inc. (ZGNX) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Zogenix, Inc.?
Stephen Farr is the chief executive officer of Zogenix, Inc. (ZGNX).
Where is Zogenix, Inc. headquartered?
Zogenix, Inc. is headquartered in United States.
Does ZGNX pay a dividend?
Zogenix, Inc. (ZGNX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did ZGNX go public?
Zogenix, Inc. (ZGNX) completed its initial public offering in 2010.